{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:43:18Z","timestamp":1789735398436,"version":"4.0.1"},"reference-count":159,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007637","name":"Departamento Administrativo de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006070","name":"Universidad de los Andes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003200","name":"Kementerian Sains, Teknologi dan Inovasi","doi-asserted-by":"publisher","award":["120380763212 \\u2013 PPTA # 8352"],"award-info":[{"award-number":["120380763212 \\u2013 PPTA # 8352"]}],"id":[{"id":"10.13039\/501100003200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003200","name":"Kementerian Sains, Teknologi dan Inovasi","doi-asserted-by":"publisher","award":["829-2018 \\u2013 PPTA # 8728"],"award-info":[{"award-number":["829-2018 \\u2013 PPTA # 8728"]}],"id":[{"id":"10.13039\/501100003200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003200","name":"Kementerian Sains, Teknologi dan Inovasi","doi-asserted-by":"publisher","award":["8729"],"award-info":[{"award-number":["8729"]}],"id":[{"id":"10.13039\/501100003200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009543","name":"Pontificia Universidad Javeriana","doi-asserted-by":"publisher","award":["8275"],"award-info":[{"award-number":["8275"]}],"id":[{"id":"10.13039\/501100009543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.heliyon.2020.e03635","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T15:48:02Z","timestamp":1585410482000},"page":"e03635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia"],"prefix":"10.1016","volume":"6","author":[{"given":"Mar\u00eda Alejandra","family":"Puentes-Tellez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Andrea","family":"Lerma-Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Guillermo","family":"Garz\u00f3n-Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-4706","authenticated-orcid":false,"given":"Diego A.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Espejo-Mojica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johana M.","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-6387","authenticated-orcid":false,"given":"Olga Yaneth","family":"Echeverri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Solano-Galarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5115-9597","authenticated-orcid":false,"given":"Alfredo","family":"Uribe-Ardila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-1173","authenticated-orcid":false,"given":"Carlos J.","family":"Alm\u00e9ciga-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.heliyon.2020.e03635_bib1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1194\/jlr.R046896","article-title":"Lysosomal exocytosis and lipid storage disorders","volume":"55","author":"Samie","year":"2014","journal-title":"J.\u00a0Lipid Res."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/14737159.2016.1121101","article-title":"Current molecular genetics strategies for the diagnosis of lysosomal storage disorders","volume":"16","author":"Giugliani","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"24","key":"10.1016\/j.heliyon.2020.e03635_bib3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","article-title":"Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening","volume":"29","author":"Kingma","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"issue":"1 suppl 1","key":"10.1016\/j.heliyon.2020.e03635_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1590\/1678-4685-gmb-2018-0159","article-title":"Lysosomal diseases: overview on current diagnosis and treatment","volume":"42","author":"Poswar","year":"2019","journal-title":"Genet. Mol. Biol."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib6","first-page":"101","article-title":"The clinical presentation of lysosomal storage disorders","volume":"13","author":"Wraith","year":"2004","journal-title":"Acta Neurol. Taiwanica"},{"issue":"Suppl. 2","key":"10.1016\/j.heliyon.2020.e03635_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1012463605992","article-title":"Variable clinical presentation in lysosomal storage disorders","volume":"24","author":"Beck","year":"2001","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib8","doi-asserted-by":"crossref","first-page":"e00527","DOI":"10.1002\/mgg3.527","article-title":"Clinical implementation of gene panel testing for lysosomal storage diseases","volume":"7","author":"Gheldof","year":"2019","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.heliyon.2020.e03635_bib9","series-title":"Fabry Disease: Perspectives from 5 Years of FOS. Oxford","article-title":"Laboratory diagnosis of lysosomal storage diseases","author":"Bekri","year":"2006"},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2020.e03635_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13052-018-0564-z","article-title":"New treatments for the mucopolysaccharidoses: from pathophysiology to therapy","volume":"44","author":"Fecarotta","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.heliyon.2020.e03635_bib11","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1038\/537S145a","article-title":"Lysosomal storage disorders","volume":"537","author":"Grayson","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2020.e03635_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib14","first-page":"233","article-title":"Vestronidase alfa: a review in mucopolysaccharidosis VII","volume":"33","author":"McCafferty","year":"2019","journal-title":"BioDrugs \u2013 Clin. Immunother. Biopharm. Gene Ther."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e03635_bib15","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","article-title":"Cerliponase alfa: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ymgme.2018.04.003","article-title":"Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): novel global treatment response model and outcomes in patients with alpha-mannosidosis","volume":"124","author":"Harmatz","year":"2018","journal-title":"Mol. Genet. Metabol."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s13104-017-2840-1","article-title":"A\u00a0first description of the Colombian national registry for rare diseases","volume":"10","author":"Mateus","year":"2017","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.heliyon.2020.e03635_bib18","series-title":"Boletin Epidemiol\u00f3gico Semanal BES - Semana Epidemiol\u00f3gica 05","author":"Sivigila","year":"2019"},{"issue":"5","key":"10.1016\/j.heliyon.2020.e03635_bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jnc.14564","article-title":"Lysosome biogenesis in health and disease","volume":"148","author":"Bajaj","year":"2019","journal-title":"J.\u00a0Neurochem."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jimd.12131","article-title":"Treating lysosomal storage disorders: what have we learnt?","volume":"43","author":"Lachmann","year":"2020","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2017.12.434","article-title":"Gene therapy for mucopolysaccharidoses","volume":"123","author":"Sawamoto","year":"2018","journal-title":"Mol. Genet. Metabol."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s10038-018-0537-5","article-title":"Gene therapy for lysosomal storage diseases and peroxisomal diseases","volume":"64","author":"Ohashi","year":"2019","journal-title":"J.\u00a0Hum. Genet."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ymgme.2018.11.011","article-title":"Enzyme enhancement therapeutics for lysosomal storage diseases: current status and perspective","volume":"126","author":"Thomas","year":"2019","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib26","series-title":"Enfermedad de Fabry: Nuevos conceptos en su historia natural, evoluci\u00f3n y tratamiento, en relaci\u00f3n a los hallazgos del Registro Fabry","author":"Politei","year":"2019"},{"key":"10.1016\/j.heliyon.2020.e03635_bib27","first-page":"91","article-title":"Fabry disease in Latin america: data from the fabry registry","volume":"8","author":"Villalobos","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.22379\/24224022123","article-title":"Mutaciones heterocigoicas en el gen de la \u03b1 - galactosidasa A en dos pacientes con ACV criptogenico","volume":"33","author":"Pe\u00f1a Guzman","year":"2017","journal-title":"Acta Neurol. Colomb."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.gene.2015.08.018","article-title":"Identification of mutations in Colombian patients affected with Fabry disease","volume":"574","author":"Uribe","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.heliyon.2020.e03635_bib30","first-page":"134","article-title":"Compromiso cardiovascular en la enfermedad de Fabry","volume":"15","author":"Bar\u00f3n","year":"2008","journal-title":"Rev. Colomb. Cardiol."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e03635_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/ijd.14330","article-title":"Angiokeratomas, not everything is Fabry disease","volume":"58","author":"Cuestas","year":"2019","journal-title":"Int. J. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib32","article-title":"Manifestaciones oculares pacientes colombianos con enfermedad de Fabry","volume":"39","author":"Rothstein","year":"2018","journal-title":"Biomedica"},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00296-019-04453-y","article-title":"Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review","volume":"40","author":"Arbel\u00e1ez-Cort\u00e9s","year":"2020","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib34","first-page":"107","article-title":"The clinical profiles of female patients with Fabry disease in Latin America: a Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status","volume":"49","author":"Martins","year":"2019","journal-title":"JIMD Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib35","first-page":"173","article-title":"Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America","volume":"77","author":"Ripeau","year":"2017","journal-title":"Medicina"},{"key":"10.1016\/j.heliyon.2020.e03635_bib36","first-page":"140","article-title":"Enfermedad de Fabry: una perspectiva hist\u00f3rica desde la semiolog\u00eda dermatol\u00f3gica hasta la correlaci\u00f3n gen\u00e9tica","volume":"34","author":"Camargo","year":"2009","journal-title":"Acta M\u00e9d. Colomb."},{"key":"10.1016\/j.heliyon.2020.e03635_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.36104\/amc.2014.269","article-title":"Enfermedad de Fabry Descripci\u00f3n de un caso y su evoluci\u00f3n en terapia de reemplazo enzim\u00e1tico","volume":"39","author":"Cantillo","year":"2014","journal-title":"Acta M\u00e9d. Colomb."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib38","first-page":"87","article-title":"Mutacion en heterocigosis en paciente con enfermedad de Gaucher tipo II","volume":"17","author":"Moreno Giraldo","year":"2015","journal-title":"Reporte de caso Gastrohnup"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib39","doi-asserted-by":"crossref","DOI":"10.29375\/01237047.3247","article-title":"Validez de la prueba de actividad enzim\u00e1tica de la glucocerebrosidasa para el diagn\u00f3stico de enfermedad de Gaucher, revisi\u00f3n sistem\u00e1tica","volume":"20","author":"Vera Cala","year":"2017","journal-title":"MedUNAB"},{"key":"10.1016\/j.heliyon.2020.e03635_bib40","first-page":"416","article-title":"Enfermedad de Gaucher: casu\u00edstica del Tolima","volume":"31","author":"Lozano","year":"2006","journal-title":"Acta M\u00e9d. Colomb."},{"key":"10.1016\/j.heliyon.2020.e03635_bib41","first-page":"273","article-title":"Enfermedad de Gaucher en Latinoam\u00e9rica\u2013un Informe del Registro Internacional Y del Grupo Latinoamericano para La enfermedad de Gaucher","volume":"72","author":"Drelichman","year":"2012","journal-title":"Medicina (Buenos Aires)"},{"key":"10.1016\/j.heliyon.2020.e03635_bib42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.17533\/udea.iatreia.v30n3a05","article-title":"Manifestaciones oculares de la enfermedad de Gaucher: presentaci\u00f3n de un caso y revisi\u00f3n del tema","volume":"30","author":"Mej\u00eda-Turizo","year":"2017","journal-title":"Iatreia"},{"issue":"4","key":"10.1016\/j.heliyon.2020.e03635_bib43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ymgme.2005.07.026","article-title":"Gaucher disease in Colombia: mutation identification and comparison to other hispanic populations","volume":"86","author":"Pomponio","year":"2005","journal-title":"Mol. Genet. Metabol."},{"issue":"8","key":"10.1016\/j.heliyon.2020.e03635_bib44","first-page":"792","article-title":"Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics","volume":"85","author":"Giraldo","year":"2000","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib45","first-page":"434","article-title":"Los haplotipos colombianos de la mutaci\u00f3n N370S causante de la enfermedad de Gaucher pueden provenir de un haplotipo ancestral com\u00fan","volume":"26","author":"Wilches","year":"2006","journal-title":"Biomedica"},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.gene.2013.03.044","article-title":"Enzymatic analysis of biomarkers for the monitoring of Gaucher patients in Colombia","volume":"521","author":"Pacheco","year":"2013","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","article-title":"CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings","volume":"114","author":"Burrow","year":"2015","journal-title":"Mol. Genet. Metabol."},{"issue":"7","key":"10.1016\/j.heliyon.2020.e03635_bib48","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"issue":"9646","key":"10.1016\/j.heliyon.2020.e03635_bib49","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.heliyon.2020.e03635_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.heliyon.2020.e03635_bib51","first-page":"39","article-title":"Identification and functional characterization of GAA mutations in Colombian patients affected by Pompe disease","volume":"7","author":"Ni\u00f1o","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib52","first-page":"231","article-title":"Enfermedad de Pompe: descripci\u00f3n de las caracter\u00edsticas cl\u00ednicas y de laboratorio de una familia colombiana","volume":"27","author":"Ortiz Giraldo","year":"2011","journal-title":"Acta Neurol. Colomb."},{"issue":"4","key":"10.1016\/j.heliyon.2020.e03635_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib54","series-title":"Adult Pompe Disease: Report of a Case as a Differential Diagnosis of Inflammatory Myopathy","author":"Lemus Barrios","year":"2019"},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib55","first-page":"33","article-title":"Enfermedad de Pompe: \u00bfEnfermedad rara o subdiagnosticada?","volume":"17","author":"Castrillon","year":"2015","journal-title":"Gastrohnup"},{"key":"10.1016\/j.heliyon.2020.e03635_bib56","series-title":"Enfermedad de Pompe: reporte de caso","first-page":"113","author":"Villate","year":"2016"},{"key":"10.1016\/j.heliyon.2020.e03635_bib57","article-title":"Understanding the early presentation of mucopolysaccharidoses disorders: results of a systematic literature review and physician survey","volume":"6","author":"Clarke","year":"2018","journal-title":"J.\u00a0Inborn Errors Metabol. Screen."},{"issue":"10","key":"10.1016\/j.heliyon.2020.e03635_bib58","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","article-title":"Therapeutic options for mucopolysaccharidoses: current and emerging treatments","volume":"79","author":"Sawamoto","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2020.e03635_bib59","first-page":"468","article-title":"Genotypic and bioinformatic evaluation of the alpha-l-iduronidase gene and protein in patients with mucopolysaccharidosis type I from Colombia, Ecuador and Peru","volume":"1","author":"Pineda","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"4","key":"10.1016\/j.heliyon.2020.e03635_bib60","doi-asserted-by":"crossref","first-page":"e0153136","DOI":"10.1371\/journal.pone.0153136","article-title":"Pentosan polysulfate: oral versus subcutaneous Injection in mucopolysaccharidosis type I dogs","volume":"11","author":"Simonaro","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib61","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metabol."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib62","article-title":"Mucopolisacaridosis tipo IH (s\u00edndrome de Hurler). Primeros Casos en Colombia","volume":"26","author":"Echeverry","year":"1995","journal-title":"Colomb. M\u00e9d."},{"key":"10.1016\/j.heliyon.2020.e03635_bib63","series-title":"A\u00a0Temporal Cluster of Mucopolysaccharidosis Type I in the Region of Sucre and Cordoba, Colombia","author":"Su\u00e1rez-Obando","year":"2017"},{"key":"10.1016\/j.heliyon.2020.e03635_bib64","first-page":"602","article-title":"Estimation of the mucopolysaccharidoses frequencies and cluster analysis in the Colombian provinces of Cundinamarca and\u00a0Boyac\u00e1","volume":"32","author":"G\u00f3mez","year":"2012","journal-title":"Biomedica \u2013 revista del Instituto Nacional de Salud"},{"issue":"4","key":"10.1016\/j.heliyon.2020.e03635_bib65","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.rchipe.2015.10.004","article-title":"Mucopolisacaridosis: caracter\u00edsticas cl\u00ednicas, diagn\u00f3stico y de manejo","volume":"87","author":"Suarez-Guerrero","year":"2016","journal-title":"Rev. Chil. Pediatr."},{"key":"10.1016\/j.heliyon.2020.e03635_bib66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7705\/biomedica.v25i2.1340","article-title":"Producci\u00f3n de anticuerpos policlonales IgG contra la prote\u00edna iduronato-2-sulfato sulfatasa y desarrollo de un sistema de detecci\u00f3n para IDS humana recombinante","volume":"25","author":"Pe\u00f1a","year":"2005","journal-title":"Biomedica"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/S1415-47572014000300003","article-title":"Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America","volume":"37","author":"Giugliani","year":"2014","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib68","first-page":"101","article-title":"Deep genotyping of the IDS gene in Colombian patients with hunter syndrome","volume":"19","author":"Galvis","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7705\/biomedica.v27i1.229","article-title":"Predicci\u00f3n computacional de la estructura terciaria de la iduronato 2-sulfato sulfatasa humana","volume":"27","author":"S\u00e1enz","year":"2007","journal-title":"Biomedica"},{"issue":"5","key":"10.1016\/j.heliyon.2020.e03635_bib70","doi-asserted-by":"crossref","first-page":"e01667","DOI":"10.1016\/j.heliyon.2019.e01667","article-title":"Identification of the iduronate-2-sulfatase proteome in wild-type mouse brain","volume":"5","author":"Cardona","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2020.e03635_bib71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.vhri.2016.01.003","article-title":"Cost-effectiveness of the quantification of enzymatic activity in leukocytes in comparison to its nonrealization for a rare disease in Latin America: the case of mucopolysaccharidosis type II in Colombia","volume":"11","author":"Parody","year":"2016","journal-title":"Val. Health Reg. Iss."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jim.2011.03.004","article-title":"Development of a sandwich enzyme linked immunosorbent assay (ELISA) for the quantification of iduronate-2-sulfate sulfatase","volume":"368","author":"Sosa","year":"2011","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.heliyon.2020.e03635_bib73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.heliyon.2020.e03635_bib74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.heliyon.2020.e03635_bib75","series-title":"Short Term Impact from Enzyme Replacement Therapy on Patients with Attenuated Hunter Syndrome (MPS II) Showing Complex Heart Disease","first-page":"S99","author":"Moreno","year":"2017"},{"issue":"8","key":"10.1016\/j.heliyon.2020.e03635_bib76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A\u00a0phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.heliyon.2020.e03635_bib77","series-title":"Successful Desensitization to Idursulfase in a Patient with Type II Mucopolysaccharidosis (Hunter Syndrome)","first-page":"571","author":"Serrano","year":"2011"},{"key":"10.1016\/j.heliyon.2020.e03635_bib78","article-title":"Laboratory scale production of the human recombinant iduronate 2-sulfate sulfatase-Like from Pichia pastoris","volume":"8","author":"C\u00f3rdoba-Ruiz","year":"2009","journal-title":"Afr. J. Biotechnol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib79","article-title":"Cloning and shake flask expression of hrIDS- like in Pichia pastoris","volume":"8","author":"Landazuri","year":"2009","journal-title":"Afr. J. Biotechnol."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib80","first-page":"213","article-title":"Low-Scale expression and purification of an active putative iduronate 2-sulfate sulfatase-Like enzyme from Escherichia coli K12","volume":"51","author":"Morales-\u00c1lvarez","year":"2013","journal-title":"J.\u00a0Microbiol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib81","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1874285801610010124","article-title":"Bioinformatic analysis of the human recombinant iduronate 2-sulfate sulfatase","volume":"10","author":"Morales-\u00c1lvarez","year":"2016","journal-title":"Open Microbiol. J."},{"issue":"5","key":"10.1016\/j.heliyon.2020.e03635_bib82","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/bab.1660","article-title":"Production and characterization of a human lysosomal recombinant iduronate-2-sulfatase produced in Pichia pastoris","volume":"65","author":"Pimentel","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib83","first-page":"75","article-title":"Expresion de Iduronato-2-Sulfato Sulfatasa humana recombiante (IDShr) en Pichia pastoris","volume":"10","author":"Poutou-Pi\u00f1ales","year":"2005","journal-title":"Univ. Sci."},{"key":"10.1016\/j.heliyon.2020.e03635_bib84","series-title":"Errores innatos del metabolismo. Un abordaje integral del diagn\u00f3stico al tratamiento","author":"Barrera","year":"2014"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0883073816672391","article-title":"Natural history of sanfilippo syndrome type C in Boyac\u00e1, Colombia:A neurogenetic description","volume":"32","author":"Velasco","year":"2017","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.15446\/rsap.v19n1.55238","article-title":"Gen\u00e9tica cl\u00ednica comunitaria: exploraci\u00f3n de patolog\u00eda gen\u00e9tica en Boyac\u00e1, Colombia","volume":"19","author":"Velasco","year":"2017","journal-title":"Revista de Salud P\u00fablica."},{"key":"10.1016\/j.heliyon.2020.e03635_bib87","series-title":"Mucopolysaccharidoses Update (2 Volume Set). I","first-page":"235","article-title":"Mucopolysaccharidosis type IVA: clinical features, Biochemistry, diagnosis, genetics, and treatment","author":"Sawamoto","year":"2018"},{"issue":"1-2","key":"10.1016\/j.heliyon.2020.e03635_bib88","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","article-title":"Mucopolysaccharidosis IVA and glycosaminoglycans","volume":"120","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13023-014-0173-x","article-title":"A\u00a0systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases","volume":"9","author":"Leadley","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.heliyon.2020.e03635_bib90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/TACG.S141881","article-title":"Determination of genotypic and clinical characteristics of Colombian patients with mucopolysaccharidosis IVA","volume":"11","author":"Tapiero-Rodriguez","year":"2018","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.heliyon.2020.e03635_bib91","first-page":"53","article-title":"Clinical and molecular characteristics of colombian patients with mucopolysaccharidosis IVA, and description of a new galns gene mutation","volume":"16","author":"Moreno","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib92","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1399-0004.2006.00670.x","article-title":"Genetic and other diseases in the pottery of Tumaco-La Tolita culture in Colombia\u2013Ecuador","volume":"70","author":"Bernal","year":"2006","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib93","doi-asserted-by":"crossref","first-page":"52","DOI":"10.33588\/rn.4801.2008483","article-title":"Possible case of Morquio syndrome in the pottery of Tumaco-Tolita culture","volume":"48","author":"Pachajoa","year":"2009","journal-title":"Rev. Neurol."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s004390050594","article-title":"A\u00a0novel common missense mutation G301C in the N-acetylgalactosamine-6-sulfate sulfatase gene in mucopolysaccharidosis IVA","volume":"101","author":"Kato","year":"1997","journal-title":"Hum. Genet."},{"issue":"9","key":"10.1016\/j.heliyon.2020.e03635_bib95","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s10038-004-0178-8","article-title":"Identification of a common mutation in mucopolysaccharidosis IVA: correlation among genotype, phenotype, and keratan sulfate","volume":"49","author":"Tomatsu","year":"2004","journal-title":"J.\u00a0Hum. Genet."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib96","first-page":"85","article-title":"Morquio syndrome: new heterozygous mutation of the GALNS gene in two siblings from south-west Colombia. Clinical, molecular, and bioinformatic analysis","volume":"83","author":"Pachajoa","year":"2016","journal-title":"Rev. Mex. Pediatr."},{"key":"10.1016\/j.heliyon.2020.e03635_bib97","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/humu.20257","article-title":"Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A)","volume":"26","author":"Tomatsu","year":"2005","journal-title":"Hum. Mutat."},{"issue":"9","key":"10.1016\/j.heliyon.2020.e03635_bib98","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/hmg\/9.9.1283","article-title":"Biochemical and structural analysis of missense mutations in N-acetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes","volume":"9","author":"Sukegawa","year":"2000","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.heliyon.2020.e03635_bib99","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s10545-007-0702-z","article-title":"Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase","volume":"30","author":"Monta\u00f1o","year":"2007","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e03635_bib100","first-page":"3958","article-title":"Structural and functional analysis of N-acetylgalactosamine-6-sulfate sulfatase using bioinformatics tools: insight into mucopolysaccharidosis IVA","volume":"4","author":"Sarath Chandar","year":"2011","journal-title":"J.\u00a0Pharm. Res."},{"issue":"5","key":"10.1016\/j.heliyon.2020.e03635_bib101","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jmb.2012.08.020","article-title":"The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A","volume":"423","author":"Rivera-Colon","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e03635_bib102","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1007\/s11033-014-3383-3","article-title":"Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A","volume":"41","author":"Olarte-Avellaneda","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib103","series-title":"Advances in Computational Biology. Proceedings of the 2nd Colombian Congress on Computational Biology and Bioinformatics (CCBCOL)","first-page":"141","article-title":"In-silico analysis of the active cavity of N-acetylgalactosamine-6-sulfate sulfatase in eight species","author":"Olarte-Avellaneda","year":"2014"},{"issue":"6","key":"10.1016\/j.heliyon.2020.e03635_bib104","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment","volume":"12","author":"Tomatsu","year":"2011","journal-title":"Curr. Pharmaceut. Biotechnol."},{"issue":"10","key":"10.1016\/j.heliyon.2020.e03635_bib105","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajmg.a.32281","article-title":"Growth charts for patients affected with Morquio A Disease","volume":"15","author":"Monta\u00f1o","year":"2008","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.heliyon.2020.e03635_bib106","first-page":"273","article-title":"Evaluation and impact on the quality of life of patients with mucopolysaccharidosis IV-A (Morquio A) at the Colombian southwestern","volume":"5","author":"Satizabal","year":"2017","journal-title":"J.\u00a0Inborn Errors Metab. Screen"},{"issue":"381","key":"10.1016\/j.heliyon.2020.e03635_bib107","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jns.2017.08.551","article-title":"School skills and neuropsychological functioning in Morquio A syndrome and Maroteaux Lamy syndrome adolescents, in bogot\u00e1, Colombia","volume":"15","author":"Ib\u00e1\u00f1ez","year":"2017","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.heliyon.2020.e03635_bib108","article-title":"Intellectual and neurological functioning in Morquio syndrome (MPSIVA)","volume":"36","author":"Davison","year":"2012","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2020.e03635_bib109","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.rh.2018.07.002","article-title":"Family quality of life in patients with Morquio type iv-A syndrome: the perspective of the colombian social context (South America)","volume":"52","author":"Ortiz-Quiroga","year":"2018","journal-title":"Rehabilitacion (Madr)"},{"issue":"11","key":"10.1016\/j.heliyon.2020.e03635_bib110","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10295-010-0766-x","article-title":"Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21","volume":"37","author":"Rodriguez","year":"2010","journal-title":"J.\u00a0Ind. Microbiol. Biotechnol."},{"issue":"5","key":"10.1016\/j.heliyon.2020.e03635_bib111","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4014\/jmb.1211.11044","article-title":"Effect of culture conditions and signal peptide on production of human recombinant N-Acetylgalactosamine-6-Sulfate sulfatase in Escherichia coli BL21","volume":"23","author":"Hern\u00e1ndez","year":"2013","journal-title":"J.\u00a0Microbiol. Biotechnol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib112","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.procbio.2012.07.028","article-title":"Characterization of a recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in E. coli for enzyme replacement therapy of Morquio A disease","volume":"47","author":"Mosquera","year":"2012","journal-title":"Process Biochem."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib113","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1038\/s41598-017-06367-w","article-title":"Improvement in the production of the human recombinant enzyme N-acetylgalactosamine-6-sulfatase (rhGALNS) in Escherichia coli using synthetic biology approaches","volume":"7","author":"Reyes","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib114","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.gene.2017.08.043","article-title":"Anaerobic sulfatase maturase AslB from Escherichia coli activates human recombinant iduronate-2-sulfate sulfatase (IDS)\u00a0and N-acetylgalactosamine-6-sulfate sulfatase (GALNS)","volume":"634","author":"Almeciga-Diaz","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.heliyon.2020.e03635_bib115","doi-asserted-by":"crossref","first-page":"29329","DOI":"10.1038\/srep29329","article-title":"Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris","volume":"6","author":"Rodr\u00edguez-L\u00f3pez","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2019.03.034","article-title":"Characterization of human recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Pichia pastoris as potential enzyme for mucopolysaccharidosis IVA treatment","author":"Rodriguez-Lopez","year":"2019","journal-title":"J.\u00a0Pharm. Sci."},{"issue":"17","key":"10.1016\/j.heliyon.2020.e03635_bib117","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1111\/j.1742-4658.2010.07769.x","article-title":"Adeno-associated virus gene transfer on Morquio A: effect of promoters and sulfatase-modifying Factor 1","volume":"277","author":"Alm\u00e9ciga-D\u00edaz","year":"2010","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.heliyon.2020.e03635_bib118","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s11033-008-9392-3","article-title":"Effect of Elongation Factor 1\u03b1 promoter and SUMF1 over in-vitro expression of N-acetylgalactosamine-6-sulfate sulfatase","volume":"36","author":"Alm\u00e9ciga-D\u00edaz","year":"2009","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib119","first-page":"448","article-title":"Construction of an adenoassociated, viral derived, expression vector to correct the genetic defect in Morquio A disease","volume":"28","author":"Gutierrez","year":"2008","journal-title":"Biomedica"},{"key":"10.1016\/j.heliyon.2020.e03635_bib120","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ymgme.2012.11.022","article-title":"New viral vectors for Morquio syndrome type A gene therapy","author":"Alm\u00e9ciga-D\u00edaz","year":"2013","journal-title":"Mol. Genet. Metabol."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib121","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2015.08.001","article-title":"Systems biology study of mucopolysaccharidosis using a human metabolic reconstruction network","volume":"117","author":"Salazar","year":"2016","journal-title":"Mol. Genet. Metabol."},{"issue":"4","key":"10.1016\/j.heliyon.2020.e03635_bib122","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41390-018-0095-8","article-title":"Tailoring the AAV2 capsid vector for bone-targeting","volume":"84","author":"Alm\u00e9ciga D\u00edaz","year":"2018","journal-title":"Pediatr. Res."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib123","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.ymgme.2018.12.305","article-title":"Evaluation of lentiviral vectors in Morquio syndrome type A patients' fibroblasts","volume":"126","author":"Puentes-Tellez","year":"2019","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib124","article-title":"Design and applications of gene therapy vectors for mucopolysaccharidosis in Colombia","author":"Alm\u00e9ciga-Diaz","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.heliyon.2020.e03635_bib125","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.9b00428","article-title":"Identification of ezetimibe and pranlukast as pharmacological chaperones for treatment of the rare disease Mucopolysaccharidosis type IVA","author":"Almeciga-Diaz","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.heliyon.2020.e03635_bib126","doi-asserted-by":"crossref","first-page":"101408","DOI":"10.1016\/j.scr.2019.101408","article-title":"Generation of an induced pluripotent stem cell line (TRNDi005-A) from a Mucopolysaccharidosis Type IVA (MPS IVA) patient carrying compound heterozygous p.R61W and p.WT405del mutations in the GALNS gene","volume":"36","author":"Li","year":"2019","journal-title":"Stem Cell Res."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib127","first-page":"221","article-title":"Colombian contribution to knowledge of Morquio A disease","volume":"34","author":"Alm\u00e9ciga-D\u00edaz","year":"2012","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10545-005-5673-3","article-title":"Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses","volume":"28","author":"Tomatsu","year":"2005","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2020.e03635_bib129","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1203\/01.PDR.0000113767.60140.E9","article-title":"Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA","volume":"55","author":"Tomatsu","year":"2004","journal-title":"Pediatr. Res."},{"issue":"Suppl 3","key":"10.1016\/j.heliyon.2020.e03635_bib130","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s10545-009-9013-x","article-title":"Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatography-tandem mass spectrometry","volume":"33","author":"Tomatsu","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib131","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","article-title":"Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial","volume":"114","author":"Hendriksz","year":"2015","journal-title":"Mol. Genet. Metabol."},{"issue":"1-2","key":"10.1016\/j.heliyon.2020.e03635_bib132","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2016.05.018","article-title":"Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome","volume":"119","author":"Hendriksz","year":"2016","journal-title":"Mol. Genet. Metabol."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib133","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajmg.a.36833","article-title":"International guidelines for the management and treatment of Morquio A syndrome","volume":"167A","author":"Hendriksz","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib134","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ymgme.2014.10.010","article-title":"Diagnostic evaluation, monitoring, and perioperative management of spinal cord compression in patients with Morquio syndrome","volume":"114","author":"Charrow","year":"2015","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib135","series-title":"Mucopolysaccharidosis Type VI: Clinical Features, Biochemistry, Diagnosis, Genetics and Treatment. Mucopolysaccharidoses Update (2 Volume Set). I","first-page":"287","author":"Tomatsu","year":"2018"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib136","doi-asserted-by":"crossref","first-page":"85","DOI":"10.25100\/cm.v45i2.1441","article-title":"Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) in the pre-Columbian culture of Colombia","volume":"45","author":"Pachajoa","year":"2014","journal-title":"Colomb. M\u00e9d."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e03635_bib137","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/medethics-2011-100204","article-title":"Ethical and economic considerations of rare diseases in ethnic minorities: the case of mucopolysaccharidosis VI in Colombia","volume":"38","author":"Rosselli","year":"2012","journal-title":"J.\u00a0Med. Ethics"},{"key":"10.1016\/j.heliyon.2020.e03635_bib138","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mgene.2015.12.004","article-title":"Molecular findings of Colombian patients with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome)","volume":"7","author":"Giraldo","year":"2016","journal-title":"Meta Gene"},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib139","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13023-018-0886-3","article-title":"Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease","volume":"13","author":"Vu","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.heliyon.2020.e03635_bib140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.11144\/Javeriana.SC21-3.corh","article-title":"Characterization of recombinant human lysosomal beta-hexosaminidases produced in the methylotrophic yeast Pichia pastoris","volume":"21","author":"Espejo-Mojica","year":"2016","journal-title":"Univ. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib141","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejmg.2014.12.009","article-title":"Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with Sandhoff disease","volume":"58","author":"Villamizar-Schiller","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.heliyon.2020.e03635_bib142","first-page":"31","article-title":"Diagn\u00f3stico bioqu\u00edmico positivo en pacientes con sospecha cl\u00ednica de Niemann Pick C","volume":"7","author":"Pardo","year":"2016","journal-title":"Ciencia en Desarrollo"},{"key":"10.1016\/j.heliyon.2020.e03635_bib143","doi-asserted-by":"crossref","first-page":"669","DOI":"10.12659\/AJCR.908808","article-title":"Lysosomal acid lipase deficiency, a rare pathology: the first pediatric patient reported in Colombia","volume":"19","author":"Botero","year":"2018","journal-title":"Am. J. Case Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib144","first-page":"e52","article-title":"Leucodistrofia metacrom\u00e1tica infantil tard\u00eda: presentaci\u00f3n de un caso","volume":"117","author":"\u00c1lvarez-Pab\u00f3na","year":"2019","journal-title":"Arch. Argent. Pediatr."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib145","first-page":"44","article-title":"Metachromatic leukodystrophy. Case presentation","volume":"46","author":"Espejo","year":"2017","journal-title":"Rev. Colomb. Psiquiatr. (Eng. Ed.)"},{"key":"10.1016\/j.heliyon.2020.e03635_bib146","doi-asserted-by":"crossref","first-page":"199","DOI":"10.17533\/udea.iatreia.v30n2a09","article-title":"Tiene el paciente una leucodistrofia? Importancia de la descripci\u00f3n cl\u00ednica, la semiolog\u00eda y las neuroim\u00e1genes ante la sospecha diagn\u00f3stica de leucodistrofia de origen metab\u00f3lico","volume":"30","author":"Echeverri-Pe\u00f1a","year":"2017","journal-title":"Iatreia"},{"issue":"7","key":"10.1016\/j.heliyon.2020.e03635_bib147","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejmg.2014.04.005","article-title":"Clinical utility of whole-exome sequencing in rare diseases: Galactosialidosis","volume":"57","author":"Prada","year":"2014","journal-title":"Eur. J. Med. Genet."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib148","first-page":"273","article-title":"Gangliosidosis GM1: a prop\u00f3sito de un caso cl\u00ednico","volume":"56","author":"Londo\u00f1o","year":"2015","journal-title":"Univ. Med."},{"key":"10.1016\/j.heliyon.2020.e03635_bib149","first-page":"37","article-title":"Gangliosidosis gml juvenil como causa de regresi\u00f3n en el neurodesarrollo: reporte de caso","volume":"28","author":"Ortiz","year":"2012","journal-title":"Acta Neurol. Colomb."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e03635_bib150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/exd.13532","article-title":"Transcriptomic analysis of FUCA1 knock-down in keratinocytes reveals new insights into the pathogenesis of fucosidosis skin lesions","volume":"27","author":"Valero-Rubio","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.heliyon.2020.e03635_bib151","first-page":"107","article-title":"Selective screening for lysosomal storage diseases with dried blood spots collected on filter paper in 4,700 high-risk colombian subjects","volume":"11","author":"Uribe","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.heliyon.2020.e03635_bib152","series-title":"13th International Congress of Inborn Errors of Metabolism - ICIEM 2017","first-page":"340","article-title":"Selective screening of 32 940 Colombian patients for the detection of lysosomal metabolic disorders: memories of 22 Years of research (1995-2016)","author":"Uribe Ardila","year":"2017"},{"key":"10.1016\/j.heliyon.2020.e03635_bib153","doi-asserted-by":"crossref","first-page":"7","DOI":"10.18359\/rmed.2875","article-title":"An\u00e1lisis de la B-galactosilceramidasa leucocitaria en pacientes colombianos con sospecha cl\u00ednica de enfermedad de Krabbe, un tamizaje de alto riesgo","volume":"25","author":"Jay Garcia","year":"2017","journal-title":"Rev. Med."},{"key":"10.1016\/j.heliyon.2020.e03635_bib154","series-title":"Enzymatic Studies of Gaucher Disease in Colombia, A Compilation of the Results of Seventeen-Years of High-Risk Screening","author":"Uribe","year":"2017"},{"key":"10.1016\/j.heliyon.2020.e03635_bib155","series-title":"Screening Tests for Pompe Disease in 6522 Samples from Colombian Patients, the Need of Confirmation","author":"Uribe","year":"2017"},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2020.e03635_bib156","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13052-018-0552-3","article-title":"Newborn screening in mucopolysaccharidoses","volume":"44","author":"Donati","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"3","key":"10.1016\/j.heliyon.2020.e03635_bib157","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","article-title":"Newborn screening for lysosomal storage disorders","volume":"39","author":"Matern","year":"2015","journal-title":"Semin. Perinatol."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib158","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1373\/clinchem.2014.225771","article-title":"Newborn screening for lysosomal storage diseases","volume":"61","author":"Gelb","year":"2015","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e03635_bib159","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ymgme.2017.03.001","article-title":"Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: three-year findings from a screening program in a closed Mexican health system","volume":"121","author":"Navarrete-Martinez","year":"2017","journal-title":"Mol. Genet. Metabol."},{"issue":"2","key":"10.1016\/j.heliyon.2020.e03635_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/ijns3020006","article-title":"Newborn screening for lysosomal storage diseases: a concise review of the literature on screening methods, therapeutic possibilities and regional programs","volume":"3","author":"Schielen","year":"2017","journal-title":"Int. J. Neonat. Screen"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020304801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020304801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:15:53Z","timestamp":1778883353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844020304801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":159,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S2405844020304801"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e03635","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e03635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e03635"}}